Letter: Response to Cost-per-Responder Analysis of Tralokinumab Versus Dupilumab for Moderate-to-Severe Atopic Dermatitis Across Universal Health Care Systems

Abstract

Get full access to this article

View all access options for this article.

References

1. Hussain

. Letter: Cost-per-responder analysis of tralokinumab versus dupilumab for moderate-to-severe atopic dermatitis across universal health care systems. Dermatitis. 2026:17103568251394011; doi: 10.1177/17103568251394011

2. Torres

, Sohrt Petersen

, Ivens

, et al. Matching-adjusted indirect comparison of the efficacy at week 32 of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(4):983–992.

3. Torres

, Ryttig

, Larsen

, et al. EE411 cost-per-responder analysis of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis. Value in Health. 2023;26(12):S130.

4. Wiseman

, Benvenuto

, Strømkjær

, et al. Cost-per-responder analysis for tralokinumab and dupilumab in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2026;16(1):265–276; doi: 10.1007/s13555-025-01565-1

5. Wu

, Balu

, Larsen

, et al. Cost-per-responder analysis of tralokinumab versus dupilumab in moderate-to-severe atopic dermatitis in North America and Europe. Br J Dermatol. 2024;190(Suppl 2):ii42–ii43; doi: 10.1093/bjd/ljad498.044